Table 1.
Anti-tumor effects of trifluridine/tipiracil (FTD/TPI) and regorafenib in mice implanted with SW620 human colorectal tumors.
| Group | Dose (mg/kg/day) | Treatment | n | RTV(mean ± SD) | TGI(%) |
|---|---|---|---|---|---|
| Control | - | - | 6 | 29.94 ± 3.40 | - |
| FTD/TPI | 150 | Day 1–14 (b.i.d.) | 6 | 14.57 ± 1.44 a | 51.3 |
| Regorafenib | 10 | Day 1–14 (q.d.) | 6 | 6.55 ± 1.34 a | 78.1 |
| FTD/TPI followed by Regorafenib | 150 + 10 | - | 6 | 4.07 ± 0.56 a,b | 86.4 |
RTV: Relative tumor volume on day 15; TGI: Tumor growth-inhibition ratio on day 15; b.i.d.: bis in die; q.d.: quaque die; a p < 0.01 with a two-sided Aspin-Welch t-test, compared to control; b p < 0.01 with a two-sided Aspin-Welch t-test, compared to either monotherapy.